Read by QxMD icon Read

Clinical Schizophrenia & related Psychoses

P Vasileiadis, G Mavridis, A Keramidas, D Chardalidou, I Pervos, C Charalampous
BACKGROUND: Chilaiditi's sign is defined as the interposition of bowels between the liver and the right diaphragm. When the patient is symptomatic due to the intestinal obstruction, the case is referred to as Chilaiditi's syndrome. OBJECTIVE: To emphasize the importance of accurate diagnose of Chilaiditi's syndrome in patients with psychotic disturbances. METHOD: A 46 years old male was admitted to our department suffering from a constant epigastric and right upper quadrant pain with radiation to the right shoulder...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Steven Berendsen, Jasper van der Paardt, Marion van Bruggen, Hans Nusselder, Margje Jalink, Jaap Peen, Henricus Van, Jack Dekker, Lieuwe de Haan
OBJECTIVE: clinical staging and profiling of schizophrenia spectrum disorders has been proposed to describe and define the heterogenous course of disease. We examined the construct validity of clinical staging in schizophrenia spectrum disorders by measuring differences in distribution and severity of relevant clinical profilers and therapeutic improvement (HoNOS) across clinical stages. METHODS: we performed a prospective cross-sectional study with 258 inpatiënts who met DSM-IV criteria for schizophrenia spectrum disorders, recruited in an acute ward of a psychiatric hospital from 1-1-2015 until 31-12-2016...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Ciaran Clarke
Although recognized as a feature of schizophrenia since the time of Kraepelin, motor disorders have received relatively little attention, particularly as regard their phenomenology. This is particularly the case in the English-speaking literature, where 'automaticity', mutism, and autonomic instability, have been emphasized among the features of catatonia at the expense of more complex behaviors and mannerisms. The possible relationship between the content of thinking disorders, such as hallucinations and dereistic thinking, and involuntary and semi-voluntary movement disorders, has been little noted...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Camila Wanderley Pereira, Isabelly Sanally Monteiro Florentino, Leonardo Machado
Cotard's Syndrome (CS), among the noncognitive changes in the forms of dementia, is a seldom-found manifestation (1). This syndrome is characterized by the delusion of having lost organs (the individual experiences huge changes in the body and believes that he/she no longer has one or more organs) and by nihilistic delusion (the individual believes he/she or everyone in the world has died or been destroyed) (2). In 1880, Jules Cotard (1840-1889) described a clinical condition that he believed corresponded to a new subtype of depression, which he called anxious melancholia...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Cintia R Prokopez, Oscar M Cesoni, Gabriela B Caporusso, María L Reffino-Pereyra, Germán Alberio, Miguel Vallejos
Patients with schizophrenia have higher rates of adverse childhood experiences (ACEs) than the general population, and those who suffered multiple traumatic experiences have a higher prevalence of positive symptoms, poorer social functioning and more suicidal ideations and behavior. The current study aims to determine the prevalence of ACEs in a female patient sample with schizophrenia. An observational descriptive cross-sectional study was conducted. Participants included 50 female patients older than 18 years, with schizophrenia...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Mina Boazak, Benjamin Kahn, Lindsay Cox, James Ragazino, David R Goldsmith, Robert O Cotes
Clozapine-induced neutropenia occurs in 3-5% of individuals treated with clozapine. Current US guidelines require interruption of clozapine when the absolute neutrophil count (ANC) drops below 1000 cells/mm3 . There is minimal available guidance for what dosing schedule to use when restarting clozapine after an episode of neutropenia. Here, we present a case of a 50-year-old Caucasian female with a history of schizoaffective disorder who was successfully rechallenged on clozapine one month after developing clozapine-induced neutropenia (ANC 600 cells/mm3 )...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Isabelly Sanally Monteiro Florentino, José Brasileiro Dourado Júnior, Amaury Cantilino
BACKGROUND: The involvement of Cryptococcus as an etiological agent in behavioral disorders, such as psychosis, is rare finding. METHODS: We report the case of 20-year-old man showed apparent functioning behavior premorbid, immunocompetent, with had a first psychotic episode one day after a clinical condition by mild fever, polyarthralgia, headache, fatigue and insomnia and detected cryptococcal antigen latex and India ink positive for Cryptococus neoformans in lumbar puncture...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Ricardo Coentre, Rodrigo Saraiva, Pedro Levy
Hypokalemia is the most frequent electrolyte abnormality seen in clinical practice. Hypokalemia is defined as serum potassium below 3.5 mEq/L and is usually asymptomatic and only identified in routine laboratory analysis. However, in some cases, symptoms include hypertension, palpitations, muscle weakness, easy fatigability, cramping and myalgias, memory impairment, disorientation and confusion, depressed or anxious mood, and irritability. Although rare, hypokalemia has been associated with psychosis. In particular, hypokalemia has been associated with psychotic exacerbations in patients with chronic psychotic disorder...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Massimiliano Buoli, Chiara Rovera, Cecilia Maria Esposito, Silvia Grassi, Wiepke Cahn, A Carlo Altamura
Aggressive behaviour represents a challenge in the treatment of patients with schizophrenia, being often associated with clinical predictors of severity of illness such as poor insight, psychotic re-exacerbation, concomitant substance misuse or comorbidity with personality disorders. As psychotic relapses and consequent risk of aggressive behaviour are often associated with a poor compliance, purpose of the present manuscript is to give an overview of the available data about the use of depot antipsychotics for the management of violence in patients with schizophrenia...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Barbara Schwartz, Theresa Teslovich, Xiaozhen You, Jae Cho, Nina Schooler, Peter Kokkinos, Chandan Vaidya
Memory impairment in schizophrenia has been linked to abnormal functioning of fronto-temporal networks. In this pilot study, we investigated whether 12-weeks of exercise improved hippocampal-dependent memory functions and resting-state functional connectivity in middle-aged adults with schizophrenia. The exercise regimen was feasible, well-attended, and safe. There was a pre- to post-intervention increase in spatial memory accuracy that was correlated to an increase in hippocampal-prefrontal cortex connectivity...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Mar Fernández-Modamio, Marta Arrieta-Rodríguez, Rosario Bengochea-Seco, Iciar Santacoloma-Cabero, Juan Gómez de Tojeiro-Roce, Bárbara García-Polavieja, Eduardo González-Fraile, Manuel Martín-Carrasco, Kim Griffin, David Gil-Sanz
Previous research on theory of mind suggests that people with schizophrenia have difficulties with complex mentalization tasks that involve the integration of cognition and affective mental states. One of the tools most commonly used to assess theory of mind is the Faux-Pas Test. However, it presents two main methodological problems: 1) the lack of a standard scoring system; 2) the different versions are not comparable due to a lack of information on the stories used. These methodological problems make it difficult to draw conclusions about performance on this test by people with schizophrenia...
June 26, 2018: Clinical Schizophrenia & related Psychoses
David Sarfati, Jonathan Lai, Howard C Margolese
BACKGROUND: Treatment-resistant schizophrenia patients frequently need to be managed with clozapine. However, noncompliance is in-part due to complaints of sedation, fatigue, and low energy. There is little literature reporting on the effectiveness and safety of using stimulants to treat clozapine-induced sedation. We report three cases of treatment-resistant schizophrenia where methylphenidate was used to address these common side-effects. METHODS: To evaluate the effectiveness and safety of psychostimulants in treatment-resistant schizophrenia, we reviewed 3 extensively documented cases of clozapine-induced sedation treated with methylphenidate for over 2 years, in addition to reviewing the literature on this topic...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Jack P Fatica, Salima Jiwani, Rabia Salman, Salman Majeed
Premenstrual psychosis is a rare phenomenon initiating during or preceding menses, often lasting one to two weeks after the onset of menses. Previous literature shows links between the estrogen decline of the menstrual cycle's late luteal phase and the worsening of preexisting symptomatology in psychosis. There is thought to be a similar etiology in premenstrual psychosis. Current literature describes mostly clinical cases showing successful treatment using oral contraceptives and/or atypical antipsychotics...
June 26, 2018: Clinical Schizophrenia & related Psychoses
Megan J Ehret, Erica Davis, Sarah E Luttrell, Caroline Clark
Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long-acting injectable (LAI) antipsychotics offer an extended dosing interval option for patients, although the current options may require an oral overlap at initiation. Aripiprazole lauroxil is an LAI that offers multiple dosing options but requires oral treatment overlap during initiation for the first 21 consecutive days. As an alternative to oral overlap, a novel nano-crystalline milled dispersion delivery system of aripiprazole lauroxil was recently approved as a one-day regimen to be added to aripiprazole lauroxil treatment...
2018: Clinical Schizophrenia & related Psychoses
Peter F Buckley
No abstract text is available yet for this article.
2018: Clinical Schizophrenia & related Psychoses
Nigel Bark, Nicholas Lawson, Eileen Trigoboff, Rodica Varadi, Jeffery Grace, Josie Olympia, Nighat Sindhu, Tom Watson, Mohamed El-Defrawi, Punyabrata Roy
So far, demographic variables have not consistently been found to predict clinical response to antipsychotics. This study examines some differences in response to ziprasidone, which has been shown to be effective, with a better metabolic side effect profile, but was little used in New York State Hospitals. The aim was to study state hospital patients switched to ziprasidone. The results led to questions about different responses in different groups. Subjects from state hospitals who needed a change of antipsychotic participated in this open-label, 8-week trial of up to 240-mg ziprasidone...
2018: Clinical Schizophrenia & related Psychoses
Sahil Munjal, Stephen Ferrando
We are presenting the case of a 37-year-old male with schizoaffective disorder who developed myocarditis within three weeks of starting on clozapine for his treatment-resistant psychosis. The patient also had a positive titer for Influenza A, which makes it a diagnostic dilemma regarding the cause of his myocarditis. It may be possible that the myocarditis was caused by the Influenza A virus or synergistically exacerbated the clozapine's propensity to cause it. Currently, there are no studies establishing the link between the two etiologies...
2018: Clinical Schizophrenia & related Psychoses
Peter F Buckley
No abstract text is available yet for this article.
January 2018: Clinical Schizophrenia & related Psychoses
Arpit Aggarwal, Lindsey Schrimpf, John Lauriello
Bipolar I disorder is a serious and disabling psychiatric illness. It is associated with a significant reduction in quality of life and an increased risk for suicide. Pharmacotherapy is essential for both the acute and maintenance treatment of bi-polar I disorder. While multiple oral medications are recommended for the maintenance treatment, there are not many long-acting injectable medications approved for this indication. New treatments that would improve patient adherence have the potential for decreasing relapses and improving patients' ability to remain functional members of society...
January 2018: Clinical Schizophrenia & related Psychoses
Michael A Cummings, George J Proctor, Stephen M Stahl
Tardive dyskinesia remains a significant, potentially stigmatizing or crippling adverse effect for any patient treated with an antipsychotic medication. While second- and third-generation antipsychotics have exhibited lower annual incidence rates for tardive dyskinesia than classic or first-generation agents, 3.9% versus 5.5%, the estimated incidence rate is only modestly lower. When coupled with the fact that second- and third-generation antipsychotic medications have come to be employed in treating a wider range of disorders (e...
January 2018: Clinical Schizophrenia & related Psychoses
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"